RAD51C is a susceptibility gene for ovarian cancer

Human Molecular Genetics

Volumn 20, Issue 16, 2011, Pages 3278-3288

  Pelttari, Liisa M ^a   Heikkinen, Tuomas ^a   Thompson, Deborah ^c   Kallioniemi, Anne ^d,e   Schleutker, Johanna ^d,e   Holli, Kaija ^e   Blomqvist, Carl ^a   Aittomäki, Kristiina ^a   Bützow, Ralf ^a,b   Nevanlinna, Heli ^a  

^a Department of Obstetrics and Gynecology ^*  (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FINLAND; GENE DELETION; GENE MUTATION; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; POPULATION GENETIC PARAMETERS; PRIORITY JOURNAL; RAD51C GENE; TUMOR GENE;

ADULT; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HAPLOTYPES; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PEDIGREE; RISK FACTORS; RNA SPLICING;

EID: 79960815893     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr229     Document Type: Article

References (57)

1. Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global cancer statistics, 2002. CA Cancer J. Clin., 55, 74-108.
2. Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet, 358, 1389-1399.
3. Antoniou, A.C., Pharoah, P.D., McMullan, G., Day, N.E., Stratton, M.R., Peto, J., Ponder, B.J. and Easton, D.F. (2002) A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer, 86, 76-83.
4. Pharoah, P.D., Antoniou, A., Bobrow, M., Zimmern, R.L., Easton, D.F. and Ponder, B.A. (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet., 31, 33-36.
5. Antoniou, A.C. and Easton, D.F. (2006) Models of genetic susceptibility to breast cancer. Oncogene, 25, 5898-5905.
6. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M. and Ding, W. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 266, 66-71.
7. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C. and Micklem, G. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789-792.
8. Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F. Jr, Nelson, C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z. and Tainsky, M.A. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233-1238.
9. Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M. et al. (1997) Germline mutations of the PTEN gene in cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet., 16, 64-67.
10. Boardman, L.A., Thibodeau, S.N., Schaid, D.J., Lindor, N.M., McDonnell, S.K., Burgart, L.J., Ahlquist, D.A., Podratz, K.C., Pittelkow, M. and Hartmann, L.C. (1998) Increased risk for cancer in patients with the peutz-jeghers syndrome. Ann. Intern. Med., 128, 896-899.
11. Watson, P. and Lynch, H.T. (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer, 71, 677-685.
12. Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., Byrd, P., Taylor, M. and Easton, D.F. (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl Cancer Inst., 97, 813-822.
13. Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R., Hollestelle, A., Houben, M., Crepin, E., van Veghel-Plandsoen, M. et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet., 31, 55-59.
14. Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., Chagtai, T. et al. (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet., 39, 165-167.
15. Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., Chagtai, T., Jayatilake, H., Ahmed, M., Spanova, K. et al. (2006) Truncating mutations in the fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet., 38, 1239-1241.
16. Ramus, S.J., Harrington, P.A., Pye, C., DiCioccio, R.A., Cox, M.J., Garlinghouse-Jones, K., Oakley-Girvan, I., Jacobs, I.J., Hardy, R.M., Whittemore, A.S. et al. (2007) Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum. Mutat., 28, 1207-1215.
17. Easton, D.F., Pooley, K.A., Dunning, A.M., Pharoah, P.D., Thompson, D., Ballinger, D.G., Struewing, J.P., Morrison, J., Field, H., Luben, R. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
18. Stacey, S.N., Manolescu, A., Sulem, P., Rafnar, T., Gudmundsson, J., Gudjonsson, S.A., Masson, G., Jakobsdottir, M., Thorlacius, S., Helgason, A. et al. (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 39, 865-869.
19. Stacey, S.N., Manolescu, A., Sulem, P., Thorlacius, S., Gudjonsson, S.A., Jonsson, G.F., Jakobsdottir, M., Bergthorsson, J.T., Gudmundsson, J., Aben, K.K. et al. (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 40, 703-706.
20. Zheng, W., Long, J., Gao, Y.T., Li, C., Zheng, Y., Xiang, Y.B., Wen, W., Levy, S., Deming, S.L., Haines, J.L. et al. (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet., 41, 324-328.
21. Ahmed, S., Thomas, G., Ghoussaini, M., Healey, C.S., Humphreys, M.K., Platte, R., Morrison, J., Maranian, M., Pooley, K.A., Luben, R. et al. (2009) Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet., 41, 585-590.
22. Song, H., Ramus, S.J., Tyrer, J., Bolton, K.L., Gentry-Maharaj, A., Wozniak, E., Anton-Culver, H., Chang-Claude, J., Cramer, D.W., DiCioccio, R. et al. (2009) A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat. Genet., 41, 996-1000.
23. Bolton, K.L., Tyrer, J., Song, H., Ramus, S.J., Notaridou, M., Jones, C., Sher, T., Gentry-Maharaj, A., Wozniak, E., Tsai, Y.Y. et al. (2010) Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat. Genet., 42, 880-884.
24. Goode, E.L., Chenevix-Trench, G., Song, H., Ramus, S.J., Notaridou, M., Lawrenson, K., Widschwendter, M., Vierkant, R.A., Larson, M.C., Kjaer, S.K. et al. (2010) A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet., 42, 874-879.
25. D'Andrea, A.D. (2010) Susceptibility pathways in fanconi's anemia and breast cancer. N. Engl. J. Med., 362, 1909-1919.
26. Howlett, N.G., Taniguchi, T., Olson, S., Cox, B., Waisfisz, Q., De Die-Smulders, C., Persky, N., Grompe, M., Joenje, H., Pals, G. et al. (2002) Biallelic inactivation of BRCA2 in fanconi anemia. Science, 297, 606-609.
27. Levitus, M., Waisfisz, Q., Godthelp, B.C., de Vries, Y., Hussain, S., Wiegant, W.W., Elghalbzouri-Maghrani, E., Steltenpool, J., Rooimans, M.A., Pals, G. et al. (2005) The DNA helicase BRIP1 is defective in fanconi anemia complementation group J. Nat. Genet., 37, 934-935.
28. Levran, O., Attwooll, C., Henry, R.T., Milton, K.L., Neveling, K., Rio, P., Batish, S.D., Kalb, R., Velleuer, E., Barral, S. et al. (2005) The BRCA1-interacting helicase BRIP1 is deficient in fanconi anemia. Nat. Genet., 37, 931-933.
29. Reid, S., Schindler, D., Hanenberg, H., Barker, K., Hanks, S., Kalb, R., Neveling, K., Kelly, P., Seal, S., Freund, M. et al. (2007) Biallelic mutations in PALB2 cause fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet., 39, 162-164.
30. Xia, B., Dorsman, J.C., Ameziane, N., de Vries, Y., Rooimans, M.A., Sheng, Q., Pals, G., Errami, A., Gluckman, E., Llera, J. et al. (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat. Genet., 39, 159-161.
31. Garcia-Higuera, I., Taniguchi, T., Ganesan, S., Meyn, M.S., Timmers, C., Hejna, J., Grompe, M. and D'Andrea, A.D. (2001) Interaction of the fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell, 7, 249-262.
32. Vaz, F., Hanenberg, H., Schuster, B., Barker, K., Wiek, C., Erven, V., Neveling, K., Endt, D., Kesterton, I., Autore, F. et al. (2010) Mutation of the RAD51C gene in a fanconi anemia-like disorder. Nat. Genet., 42, 406-409.
33. Meindl, A., Hellebrand, H., Wiek, C., Erven, V., Wappenschmidt, B., Niederacher, D., Freund, M., Lichtner, P., Hartmann, L., Schaal, H. et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet., 42, 410-414.
34. Dosanjh, M.K., Collins, D.W., Fan, W., Lennon, G.G., Albala, J.S., Shen, Z. and Schild, D. (1998) Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes. Nucleic Acids Res., 26, 1179-1184.
35. Takata, M., Sasaki, M.S., Tachiiri, S., Fukushima, T., Sonoda, E., Schild, D., Thompson, L.H. and Takeda, S. (2001) Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs. Mol. Cell Biol., 21, 2858-2866.
36. Badie, S., Liao, C., Thanasoula, M., Barber, P., Hill, M.A. and Tarsounas, M. (2009) RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation. J. Cell Biol., 185, 587-600.
37. Jones, S., Hruban, R.H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D.W., Lin, J.C., Palmisano, E., Brune, K., Jaffee, E.M. et al. (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 324, 217.
38. Heikkinen, T., Karkkainen, H., Aaltonen, K., Milne, R.L., Heikkila, P., Aittomaki, K., Blomqvist, C. and Nevanlinna, H. (2009) The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res., 15, 3214-3222.
39. Sarantaus, L., Huusko, P., Enrola, H., Launonen, V., Vehmanen, P., Rapakko, K., Gillanders, E., Syrjakoski, K., Kainu, T., Vahteristo, P. et al. (2000) Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in finland. Eur. J. Hum. Genet., 8, 757-763.
40. Auranen, A., Grenman, S., Makinen, J., Pukkala, E., Sankila, R. and Salmi, T. (1996) Borderline ovarian tumors in finland: Epidemiology and familial occurrence. Am. J. Epidemiol., 144, 548-553.
41. Crum, C.P. (2009) Intercepting pelvic cancer in the distal fallopian tube: Theories and realities. Mol. Oncol., 3, 165-170.
42. Romero, A., Perez-Segura, P., Tosar, A., Garcia-Saenz, J.A., Diaz-Rubio, E., Caldes, T. and de la Hoya, M. (2011) A HRM-based screening method detects RAD51C germ-line deleterious mutations in spanish breast and ovarian cancer families. Breast Cancer Res. Treat., in press.
43. Zheng, Y., Zhang, J., Hope, K., Niu, Q., Huo, D. and Olopade, O.I. (2010) Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res. Treat., 124, 857-861.
44. Akbari, M.R., Tonin, P., Foulkes, W.D., Ghadirian, P., Tischkowitz, M. and Narod, S.A. (2010) RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res., 12, 404.
45. Silvestri, V., Rizzolo, P., Falchetti, M., Zanna, I., Masala, G., Palli, D. and Ottini, L. (2011) Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res., 13, 404.
46. Peltonen, L., Jalanko, A. and Varilo, T. (1999) Molecular genetics of the finnish disease heritage. Hum. Mol. Genet., 8, 1913-1923.
47. Arcos-Burgos, M. and Muenke, M. (2002) Genetics of population isolates. Clin. Genet., 61, 233-247.
48. Roa, B.B., Boyd, A.A., Volcik, K. and Richards, C.S. (1996) Ashkenazi jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet., 14, 185-187.
49. Thorlacius, S., Olafsdottir, G., Tryggvadottir, L., Neuhausen, S., Jonasson, J.G., Tavtigian, S.V., Tulinius, H., Ogmundsdottir, H.M. and Eyfjord, J.E. (1996) A single BRCA2 mutation in male and female breast cancer families from iceland with varied cancer phenotypes. Nat. Genet., 13, 117-119.
50. Ramus, S.J., Kote-Jarai, Z., Friedman, L.S., van der Looij, M., Gayther, S.A., Csokay, B., Ponder, B.A. and Olah, E. (1997) Analysis of BRCA1 and BRCA2 mutations in hungarian families with breast or breast-ovarian cancer. Am. J. Hum. Genet., 60, 1242-1246.
51. Van Der Looij, M., Szabo, C., Besznyak, I., Liszka, G., Csokay, B., Pulay, T., Toth, J., Devilee, P., King, M.C. and Olah, E. (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in hungary. Int. J. Cancer, 86, 737-740.
52. Erkko, H., Xia, B., Nikkila, J., Schleutker, J., Syrjakoski, K., Mannermaa, A., Kallioniemi, A., Pylkas, K., Karppinen, S.M., Rapakko, K. et al. (2007) A recurrent mutation in PALB2 in finnish cancer families. Nature, 446, 316-319.
53. Vahteristo, P., Bartkova, J., Eerola, H., Syrjakoski, K., Ojala, S., Kilpivaara, O., Tamminen, A., Kononen, J., Aittomaki, K., Heikkila, P. et al. (2002) A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet., 71, 432-438.
54. Bartek, J. and Lukas, J. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3, 421-429.
55. Erkko, H., Dowty, J.G., Nikkila, J., Syrjakoski, K., Mannermaa, A., Pylkas, K., Southey, M.C., Holli, K., Kallioniemi, A., Jukkola-Vuorinen, A. et al. (2008) Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin. Cancer Res., 14, 4667-4671.
56. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am. J. Hum. Genet., 74, 1175-1182.
57. Syrjakoski, K., Vahteristo, P., Eerola, H., Tamminen, A., Kivinummi, K., Sarantaus, L., Holli, K., Blomqvist, C., Kallioniemi, O.P., Kainu, T. et al. (2000) Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected finnish breast cancer patients. J. Natl Cancer Inst., 92, 1529-1531.